{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T08:44:52Z","timestamp":1771145092060,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) has been associated with greater risk of recurrent wheezing and subsequent asthma. However, it is still unclear whether this association is causal or not. RSV-specific monoclonal antibodies have been shown to reduce RSV-related hospitalisations in high-risk infants, i.e. those born pre-term, but the longer term follow-up has given conflicting evidence for the prevention of recurrent wheeze or asthma.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>We aim to perform a systematic review and meta-analysis to determine whether or not prophylaxis with a monoclonal antibody for prevention of RSV-bronchiolitis reduces the risk of subsequent recurrent wheeze or asthma. If so, this would support the hypothesis that the association between RSV and recurrent wheeze and\/or asthma is causative.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>To identify relevant studies, we will search a number of databases including Medline, Embase, PubMed and Web of Science and will also manually look for unpublished data by contacting the manufacturers of monoclonal antibodies. The intervention being investigated is RSV-specific monoclonal antibody prophylaxis, and the outcome being measured is recurrent wheeze and\/or asthma. Studies will be screened according to inclusion\/exclusion criteria, to include primary studies of any study design type. Eligible studies will then be evaluated for quality and assessed for bias independently by three reviewers using the \u2018Grading of Recommendations Assessment, Development and Evaluation\u2019 (GRADE) approach. The results of the studies will be extracted into 2\u2009\u00d7\u20092 outcome tables, and a meta-analysis will be carried out to produce forest plots based on relative risk. Heterogeneity will be assessed using the <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistic. The statistical software we will use is StatsDirect.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>This review will aid in determining if the relationship between RSV and asthma development is a causal one, by showing the effect (if any) of RSV prophylaxis on subsequent recurrent wheeze\/asthma. If this study shows RSV prophylaxis to have no effect on the outcome of recurrent wheeze\/asthma, the question of causality remains.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13643-019-1251-x","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T19:08:03Z","timestamp":1576782483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a protocol for a systematic review"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-9075","authenticated-orcid":false,"given":"Lauren Alexandra","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen E.","family":"Groves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1757-7241-22-23","volume":"22","author":"K \u00d8ymar","year":"2014","unstructured":"\u00d8ymar K, Skjerven HO, Mikalsen IB. Acute bronchiolitis in infants, a review. Scand J Trauma Resusc Emerg Med. 2014;22:23. Published 2014 Apr 3. https:\/\/doi.org\/10.1186\/1757-7241-22-23.","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"2","key":"1251_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/thoraxjnl-2017-210149","volume":"73","author":"ER van Meel","year":"2018","unstructured":"van Meel ER, den Dekker HT, Elbert NJ, Jansen PW, Moll HA, Reiss IK, de Jongste JC, Jaddoe VWV, Duijts L. A population-based prospective cohort study examining the influence of early-life respiratory tract infections on school-age lung function and asthma. Thorax. 2018;73(2):167\u201373.","journal-title":"Thorax"},{"issue":"6","key":"1251_CR3","doi-asserted-by":"publisher","first-page":"e0157446","DOI":"10.1371\/journal.pone.0157446","volume":"11","author":"Z Stranak","year":"2016","unstructured":"Stranak Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS One. 2016;11(6):e0157446.","journal-title":"PLoS One"},{"issue":"5","key":"1251_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jaci.2013.12.1082","volume":"133","author":"S-v der Voort AMM","year":"2014","unstructured":"der Voort AMM S-v, Arends LR, de Jongste JC, Annesi-Maesano I, Arshad SH, Barros H, et al. Preterm birth, infant weight gain, and childhood asthma risk: a meta-analysis of 147,000 European children. J Allergy Clin Immunol. 2014;133(5):1317\u201329.","journal-title":"J Allergy Clin Immunol"},{"issue":"30","key":"1251_CR5","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.jaci.2011.12.981","volume":"129","author":"JA Krishnan","year":"2012","unstructured":"Krishnan JA, Lemanske RF, Canino GJ, Elward KS, Kattan M, Matsui EC, et al. Asthma Outcomes: Asthma Symptoms. J Allergy Clin Immunol. 2012;129(30):S124\u201335.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1251_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ppul.20486","volume":"41","author":"R Oostenbrink","year":"2006","unstructured":"Oostenbrink R, Jansingh-Piepers EM, Raat H, Nuijsink M, Landgraf JM, Essink-Bot ML, et al. Health-related quality of life of pre-school children with wheezing illness. Pediatr Pulmonol. 2006;41(10):993\u20131000.","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"1251_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/thx.2009.115188","volume":"65","author":"J Mallol","year":"2010","unstructured":"Mallol J, Garcia-Marcos L, Sole D, Brand P. International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources. Thorax. 2010;65(11):1004\u20139.","journal-title":"Thorax"},{"issue":"9","key":"1251_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","volume":"5","author":"JB Soriano","year":"2017","unstructured":"Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691\u2013706.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1251_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12916-016-0657-8","volume":"14","author":"M Mukherjee","year":"2016","unstructured":"Mukherjee M, Stoddart A, Gupta RP, Nwaru BI, Farr A, Heaven M, et al. The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med. 2016;14(1):113. Available from. https:\/\/doi.org\/10.1186\/s12916-016-0657-8.","journal-title":"BMC Med"},{"issue":"3","key":"1251_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MOO.0000000000000262","volume":"24","author":"PA Loftus","year":"2016","unstructured":"Loftus PA, Wise SK. Epidemiology of asthma. Curr Opin Otolaryngol Head Neck Surg. 2016;24(3):245\u20139.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"1","key":"1251_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1164\/rccm.201405-0901PP","volume":"191","author":"AS Feldman","year":"2015","unstructured":"Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med. 2015;191(1):34\u201344.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1251_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/all.13347","volume":"73","author":"S T\u00f6rm\u00e4nen","year":"2018","unstructured":"T\u00f6rm\u00e4nen S, Lauhkonen E, Riikonen R, Koponen P, Huhtala H, Helminen M. Risk factors for asthma after infant bronchiolitis. Allergy. 2018;73(4):916\u201322.","journal-title":"Allergy"},{"issue":"10","key":"1251_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/02770900802569991","volume":"45","author":"G Piedimonte","year":"2008","unstructured":"Piedimonte G, Perez MK. Role of early-life environmental influences in the development of asthma. How painful is it when you catch a bad cold too early? J Asthma. 2008;45(10):25\u20138.","journal-title":"J Asthma"},{"key":"1251_CR14","unstructured":"Utrecht University. First consortium of local manufacturers to make affordable biosimilars available for low income countries. https:\/\/www.uu.nl\/en\/news\/first-consortium-of-local-manufacturers-to-make-affordable-biosimilars-available-for-low-income Accessed 5 Mar 2019."},{"issue":"3","key":"1251_CR15","doi-asserted-by":"publisher","first-page":"ofy031","DOI":"10.1093\/ofid\/ofy031","volume":"5","author":"N Olchanski","year":"2018","unstructured":"Olchanski N, Hansen RN, Pope E, D\u2019Cruz B, Fergie J, Goldstein M, et al. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open forum Infect Dis. 2018;5(3):ofy031.","journal-title":"Open forum Infect Dis"},{"issue":"8","key":"1251_CR16","first-page":"769","volume":"56","author":"AL Rogovik","year":"2010","unstructured":"Rogovik AL, Carleton B, Solimano A, Goldman RD. Palivizumab for the prevention of respiratory syncytial virus infection. Can Fam Physician. 2010;56(8):769\u201372.","journal-title":"Can Fam Physician"},{"issue":"2","key":"1251_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nsmb.1723","volume":"17","author":"JS McLellan","year":"2010","unstructured":"McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol. 2010;17(2):248\u201350.","journal-title":"Nat Struct Mol Biol"},{"issue":"9","key":"1251_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","volume":"13","author":"R Bernhard","year":"2017","unstructured":"Bernhard R. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138\u201349.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1251_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4161\/mabs.1.5.9496","volume":"1","author":"O Cingoz","year":"2009","unstructured":"Cingoz O. Motavizumab. MAbs [Internet]. 2009;1(5):439\u201342.","journal-title":"MAbs [Internet]"},{"issue":"1","key":"1251_CR20","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1542\/peds.2008-1036","volume":"125","author":"X Carbonell-Estrany","year":"2010","unstructured":"Carbonell-Estrany X, Simoes EAF, Dagan R, Hall CB, Harris B, Hultquist M, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35\u201351.","journal-title":"Pediatrics"},{"key":"1251_CR21","unstructured":"Walker EP. FDA Advisers Turn Down New RSV Drug. https:\/\/www.medpagetoday.com\/publichealthpolicy\/fdageneral\/20456 Accessed 5 Mar 2019."},{"key":"1251_CR22","volume-title":"AstraZeneca drops lung drug and takes $445 million charge","author":"B Herschler","year":"2010","unstructured":"Herschler B. 2010. \u2018AstraZeneca drops lung drug and takes $445 million charge.\u2019 Reuters. https:\/\/uk.reuters.com\/article\/uk-astrazeneca-motavizumab\/astrazeneca-drops-lung-drug-and-takes-445-million-charge-idUKTRE6BK17K20101221"},{"key":"1251_CR23","unstructured":"Taylor P. Regeneron drops RSV drug. http:\/\/www.pmlive.com\/pharma_news\/regeneron_drops_rsv_drug_1202187 Accessed 5 Mar 2019."},{"issue":"10","key":"1251_CR24","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","volume":"18","author":"NI Mazur","year":"2018","unstructured":"Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295\u2013311.","journal-title":"Lancet Infect Dis"},{"issue":"338","key":"1251_CR25","first-page":"b1935","volume":"11","author":"A Teale","year":"2009","unstructured":"Teale A, Deshpande S, Burls A. Palivizumab and the importance of cost effectiveness. BMJ. 2009;11(338):b1935 Available from: http:\/\/www.bmj.com\/content\/338\/bmj.b1935.abstract.","journal-title":"BMJ"},{"issue":"3","key":"1251_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3111\/13696998.2010.499749","volume":"13","author":"KA Smart","year":"2010","unstructured":"Smart KA, Lanctot KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010;13(3):453\u201363 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20653398.","journal-title":"J Med Econ"},{"issue":"9","key":"1251_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/01.inf.0000136869.21397.6b","volume":"23","author":"J Figueras-Aloy","year":"2004","unstructured":"Figueras-Aloy J, Carbonell-Estrany X, Quero J, Group IS. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815\u201320 Available from: http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15361718.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1251_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1465-9921-9-78","volume":"9","author":"EAF Sim\u00f5es","year":"2008","unstructured":"Sim\u00f5es EAF, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9(1):78 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19063742.","journal-title":"Respir Res"},{"issue":"9181","key":"1251_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","volume":"354","author":"EAF Simoes","year":"1999","unstructured":"Simoes EAF. Respiratory syncytial virus infection. Lancet. 1999;354(9181):847\u201352 Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673699800403.","journal-title":"Lancet"},{"key":"1251_CR30","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org\/handbook."},{"key":"1251_CR31","volume-title":"The Cochrane Collaboration","author":"JJ Deeks","year":"2011","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 11: Presenting results and \u2018Summary of findings tables\u2019 Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). In: The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org."},{"key":"1251_CR32","volume-title":"The Cochrane Collaboration","author":"JJ Deeks","year":"2011","unstructured":"Deeks JJ, JPT H, Altman DG. Chapter 12: Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). In: The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org."},{"key":"1251_CR33","volume-title":"StatsDirect statistical software","author":"StatsDirect Ltd","year":"2013","unstructured":"StatsDirect Ltd. StatsDirect statistical software. http:\/\/www.statsdirect.com. England: StatsDirect Ltd.; 2013."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1251-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-1251-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1251-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:59:57Z","timestamp":1608253197000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-1251-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-1251-x","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HE Groves has delivered a presentation on her research at a non-promotional educational meeting and received honoria from Abbvie. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"333"}}